As part of the PRIDE study, dose escalation will be carried out, but the VEGF inhibitor bevacizumab will be administered twice concomitantly with the radiochemotherapy in order to counteract the increased side effects of escalation. As a result, we expect the side effect profile of dose-escalated radiochemotherapy to be comparable to that of standard therapy with 60 Gy. The aim of the study is to achieve improved overall survival without a significant increase in the rate of side effects.